Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment

Sun, Hao; Zhang, Tianyuan

doi:10.1007/s40259-022-00555-5

Cited by 13 publications

(9 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fluidity of the lipid bilayer membrane is beneficial for passive exogenous loading methods [147]. One of the passive encapsulation methods is co-incubate the cargoes with exosomes under suitable temperature and pH so that the cargoes could diffuse into exosomes through the membrane.…”

Section: Active Encapsulation Methodsmentioning

confidence: 99%

Native and engineered exosomes for inflammatory disease

Liu

Fan

et al. 2022

Nano Res.

View full text Add to dashboard Cite

Exosomes are extracellular vesicles which carry specific molecular information from donor cells and act as an intercellular communication vehicle, which have emerged as a novel cell-free strategy for the treatment of many diseases including inflammatory disease. Recently, rising studies have developed exosome-based strategies for novel inflammation therapy due to their biocompatibility and bioactivity. Researchers not only use native exosomes as therapeutic agents for inflammation, but also strive to make up for the natural defects of exosomes through engineering methods to improve and update the property of exosomes for enhanced therapeutic effects. The engineered exosomes can improve cargo-loading efficiency, targeting ability, stability, etc., to achieve combined and diverse treatment strategies in inflammation diseases. Herein, a comprehensive overview of the recent advances in application studies of native and engineered exosomes as well as the engineered methods is provided. Meanwhile, potential application prospects, possible challenges, and the development of clinical researches of exosome treatment strategy are concluded from plentiful examples, which may be able to provide guidance and suggestions for the future research and application of exosomes.

show abstract

Section: Active Encapsulation Methodsmentioning

confidence: 99%

Native and engineered exosomes for inflammatory disease

Liu

Fan

et al. 2022

Nano Res.

View full text Add to dashboard Cite

show abstract

“…MSC–EVs from the human BM may regulate the levels of maturation and activation markers (CD83, CD38, and CD80) and inflammatory cytokines [interleukin (IL)-6, IL-12p70, and TGF-β] in vitro via regulating the CCR7 gene by carrying miR-21-5p[ 42 ]. Additionally, the emerging role of MSC–EVs in facilitating pulmonary epithelium repair, rescuing mitochondrial dysfunction, and restoring pulmonary vascular leakage has been shown[ 43 , 44 ]. Therefore, regulating the maturation of DC cells in the early stage of lung injury can effectively alleviate secondary lung injury[ 45 ] (Table 1 ).…”

Section: Current Basic Research For the Use Of Mscs In Ards Treatmentmentioning

confidence: 99%

Current status and prospects of basic research and clinical application of mesenchymal stem cells in acute respiratory distress syndrome

Liang¹,

Lu²,

Tang³

et al. 2023

World J Stem Cells

View full text Add to dashboard Cite

Acute respiratory distress syndrome (ARDS) is a common and clinically devastating disease that causes respiratory failure. Morbidity and mortality of patients in intensive care units are stubbornly high, and various complications severely affect the quality of life of survivors. The pathophysiology of ARDS includes increased alveolar–capillary membrane permeability, an influx of protein-rich pulmonary edema fluid, and surfactant dysfunction leading to severe hypoxemia. At present, the main treatment for ARDS is mechanical treatment combined with diuretics to reduce pulmonary edema, which primarily improves symptoms, but the prognosis of patients with ARDS is still very poor. Mesenchymal stem cells (MSCs) are stromal cells that possess the capacity to self-renew and also exhibit multilineage differentiation. MSCs can be isolated from a variety of tissues, such as the umbilical cord, endometrial polyps, menstrual blood, bone marrow, and adipose tissues. Studies have confirmed the critical healing and immunomodulatory properties of MSCs in the treatment of a variety of diseases. Recently, the potential of stem cells in treating ARDS has been explored via basic research and clinical trials. The efficacy of MSCs has been shown in a variety of in vivo models of ARDS, reducing bacterial pneumonia and ischemia-reperfusion injury while promoting the repair of ventilator-induced lung injury. This article reviews the current basic research findings and clinical applications of MSCs in the treatment of ARDS in order to emphasize the clinical prospects of MSCs.

show abstract

“…[9] Further studies demonstrated that exosomes contain various anti-inflammatory and immunomodulatory substances, thereby reducing the inflammatory levels at the injured sites. [10] This finding further inspired a novel cellfree treatment strategy by directly using MSCs-derived exosomes as biological agents for the inflammatory treatment. [11] Despite the bright promise of MSCs-based therapy demonstrated in the inflammatory treatments in laboratory studies, their therapeutic applications in clinical bench are facing several challenges.…”

Section: Introductionmentioning

confidence: 99%

“…[ 9 ] Further studies demonstrated that exosomes contain various anti‐inflammatory and immunomodulatory substances, thereby reducing the inflammatory levels at the injured sites. [ 10 ] This finding further inspired a novel cell‐free treatment strategy by directly using MSCs‐derived exosomes as biological agents for the inflammatory treatment. [ 11 ]…”

Section: Introductionmentioning

confidence: 99%

A large‐scale production of mesenchymal stem cells and their exosomes for an efficient treatment against lung inflammation

Zhang,

Lin,

et al. 2024

Biotechnology Journal

Self Cite

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) and their produced exosomes have demonstrated inherent capabilities of inflammation‐guided targeting and inflammatory modulation, inspiring their potential applications as biologic agents for inflammatory treatments. However, the clinical applications of stem cell therapies are currently restricted by several challenges, and one of them is the mass production of stem cells to satisfy the therapeutic demands in the clinical bench. Herein, a production of human amnion‐derived MSCs (hMSCs) at a scale of over 1 × 109 cells per batch was reported using a three‐dimensional (3D) culture technology based on microcarriers coupled with a spinner bioreactor system. The present study revealed that this large‐scale production technology improved the inflammation‐guided migration and the inflammatory suppression of hMSCs, without altering their major properties as stem cells. Moreover, these large‐scale produced hMSCs showed an efficient treatment against the lipopolysaccharide (LPS)‐induced lung inflammation in mice models. Notably, exosomes collected from these large‐scale produced hMSCs were observed to inherit the efficient inflammatory suppression capability of hMSCs. The present study showed that 3D culture technology using microcarriers coupled with a spinner bioreactor system can be a promising strategy for the large‐scale expansion of hMSCs with improved anti‐inflammation capability, as well as their secreted exosomes.

show abstract

Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment

Cited by 13 publications

References 153 publications

Native and engineered exosomes for inflammatory disease

Native and engineered exosomes for inflammatory disease

Current status and prospects of basic research and clinical application of mesenchymal stem cells in acute respiratory distress syndrome

A large‐scale production of mesenchymal stem cells and their exosomes for an efficient treatment against lung inflammation

Contact Info

Product

Resources

About